An observational study in Acute Myeloid Leukemia, sponsored by Turkish Hematology Association. Recruiting at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-07.
Sponsored by Turkish Hematology Association · Observational
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.
Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.
All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.
5,441 studies on the registry are indexed under Leukemia; 637 are open to participants now.
This study's planned enrollment of 250 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →Turkish Hematology Association is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All AML patients diagnosed after 1 Jan 2020 will be included to this study.
Exclusion Criteria:
Overall Survival
From diagnosis to exits by any cause
Time frame: 60 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Turkish Hematology Association